表纸
市场调查报告书

血友病的全球市场分析:考察,趋势,预测

Global Hemophilia Market Report: Insights, Trends and Forecast (2019-2023)

出版商 Koncept Analytics 商品编码 879100
出版日期 内容资讯 英文 106 Pages
订单完成后即时交付
价格
Back to Top
血友病的全球市场分析:考察,趋势,预测 Global Hemophilia Market Report: Insights, Trends and Forecast (2019-2023)
出版日期: 2019年07月01日内容资讯: 英文 106 Pages
简介

本报告提供全球血友病市场相关分析,疾病概要和主要的诊断、治疗方法,全球整体的市场规模 - 患者数,治疗药的销售量 - 趋势预测 (各类型,各重症度,治疗的各类型,各治疗计划),各地区的详细趋势,主要的推动及阻碍市场要素,主要企业简介等调查。

第1章 市场概要

  • 所谓血友病
  • 血友病的种类
  • 前兆、症状
  • 血友病的诊断方法
  • 血友病的治疗方法

第2章 全球市场分析

  • 市场规模 (以金额为准)
  • 市场规模的预测值 (以金额为准)
  • 市场规模:各治疗计划
  • 市场规模:各类型
    • A型血友病市场预测价值 (以金额为准)
    • A型血友病市场:各重症度
    • A型血友病市场:治疗的各类型 (预防/对症疗法)
    • A型血友病市场:各治疗计划
    • B型血友病市场预测价值 (以金额为准)
    • B型血友病市场:各重症度
    • B型血友病市场:治疗的各类型
    • B型血友病市场:各治疗计划

第3章 地区市场分析

  • 美国
    • 市场规模 (以金额为准)
    • 市场规模的预测值 (以金额为准)
    • 市场规模:各类型 (以金额为准)
    • 市场规模的预测值:各类型 (以金额为准)
    • A型血友病市场 - 治疗完毕患者数的预测值
    • A型血友病市场 - 预防治疗中的重病患者数
    • A型血友病市场 - 对症疗法中的重病患者数
    • A型血友病市场 - 预防治疗中的小病、中症患者数
    • A型血友病市场 - 对症疗法中的小病、中症患者数
    • B型血友病市场 - 治疗完毕患者数的预测值
    • B型血友病市场 - 预防治疗中的重病患者数
    • B型血友病市场 - 对症疗法中的重病患者数
    • B型血友病市场 - 预防治疗中的小病、中症患者数
    • B型血友病市场 - 对症疗法中的小病、中症患者数
  • 欧洲
    • 血友病市场:患者数的预测值
    • A型血友病市场:患者数的预测值
    • B型血友病市场:患者数的预测值

第4章 市场动态

  • 成长促进因素
  • 市场主要趋势和机会
  • 课题

第5章 竞争环境

  • 全球市场
    • A型血友病:各企业市场占有率
    • A型血友病第八凝血因子:各产品市场占有率
    • A型血友病第八凝血因子遗传基因疗法:市场占有率,预测值
    • B型血友病:各企业市场占有率
    • B型血友病第九凝血因子:各产品市场占有率,预测值
    • B型血友病第九凝血因子遗传基因疗法:市场占有率,预测值
  • 美国市场
    • A型血友病市场:各企业市场占有率
  • 欧洲市场
    • A型血友病市场:各企业市场占有率

第6章 企业简介

  • Pfizer Inc.
    • 产业概要
    • 主要的财务指标
    • 事业策略
  • Bayer Group
  • Sanofi S.A.
  • 武田药品工业
  • Novo Nordisk
  • CSL Limited
目录

The global hemophilia market is estimated to reach US$12.98 billion in 2023, holding a CAGR of 6.21% in the duration spanning 2018-2023. The factors such as rise in diagnoses rate of hemophilia, rise in global healthcare expenditure and shifting focus to extended half-life (EHL) therapies are expected to drive the growth of the global hemophilia market. However, growth of the industry will be challenged by high price of treatment and reluctance to switch to new therapies. A few notable trends include shifting focus to Extended Half Life (EHL) therapies, development of novel hemophilia treatments and popularity of gene therapy.

The global hemophilia market comprises of two major segments: hemophilia A and hemophilia B. hemophilia A is four time prevalent than hemophilia B. The growing incidences of hemophilia A at vast rate has driven the increased demand for anti-hemophilia A or clotting factor VIII drugs. The pharmaceutical industry is flooded with drugs to be used in the treatment of type A, and thereby providing scope for the expansion of the global hemophilia market.

The fastest growing regional market in the hemophilia space is the U.S. due to High prevalence of hemophilia, coupled with rising inclination toward prophylaxis treatment. Rise in the population of hemophilia patients, is augmenting the need for more significant treatment methods. A lot of anti-hemophilia products are available in the market and several drugs are still in their late stage clinical process by large pharmaceutical firms. Furthermore, The U.S. and Europe are the highly established premium markets that contribute to considerable shares in the global hemophilia market.

Scope of the report:

The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B.

The major regional markets (the U.S. and Europe) have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Bayer Group, Sanofi S.A., Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail.

Key Target Audience:

  • Hemophilia Drugs Manufacturers
  • Raw Material Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Hemophilia
  • 1.2 Types of Hemophilia
  • 1.3 Signs & Symptoms
  • 1.4 Diagnosis of Hemophilia
  • 1.5 Treatment of Hemophilia

2. Global Market Analysis

  • 2.1 Global Hemophilia Market by Value
  • 2.2 Global Hemophilia Market Forecast by Value
  • 2.3 Global Hemophilia Market by Treatment Regimen
  • 2.4 Global Hemophilia Market by Type
    • 2.4.1 Global Hemophilia A Market Forecast by Value
    • 2.4.2 Global Hemophilia A Market by Severity
    • 2.4.3 Global Hemophilia A Market by Treatment Type
    • 2.4.4 Global Hemophilia A Market by Treatment Regimen
    • 2.4.5 Global Hemophilia B Market Forecast by Value
    • 2.4.6 Global Hemophilia B Market by Severity
    • 2.4.7 Global Hemophilia B Market by Treatment Type
    • 2.4.8 Global Hemophilia B Market by Treatment Regimen

3. Regional Market Analysis

  • 3.1 The U.S.
    • 3.1.1 The U.S. Hemophilia Market by Value
    • 3.1.2 The U.S. Hemophilia Market Forecast by Value
    • 3.1.3 The U.S. Hemophilia Market by Type
    • 3.1.4 The U.S. Hemophilia A Market Forecast by Value
    • 3.1.5 The US Hemophilia A Market-Treated Patient Volume Forecast
    • 3.1.6 The US Hemophilia A Market-Severe Patients on Prophylactic Therapy
    • 3.1.7 The US Hemophilia A Market-Severe Patients on On-Demand Therapy
    • 3.1.8 The US Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy
    • 3.1.9 The US Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy
    • 3.1.10 The US Hemophilia B Market Forecast by Value
    • 3.1.11 The US Hemophilia B Market- Treated Patients Volume Forecast
    • 3.1.12 The US Hemophilia B Market- Severe Patients on Prophylaxis Therapy
    • 3.1.13 The US Hemophilia B Market- Severe Patients on On-Demand Therapy
    • 3.1.14 The US Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy
    • 3.1.15 The US Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy
  • 3.2 Europe
    • 3.2.1 Europe's Hemophilia Market- Patient Volume Forecast
    • 3.2.2 Europe's Hemophilia A Market- Patient Volume Forecast
    • 3.2.3 Europe's Hemophilia B Market- Patient Volume Forecast

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Increased Focus on Prophylactic Treatment
    • 4.1.2 Increasing Diagnosis Rate
    • 4.1.3 Rise in Global Healthcare Expenditure
  • 4.2 Key Trends & Development
    • 4.2.1 Shifting Focus to Extended Half Life Therapies
    • 4.2.2 Development of Novel Hemophilia Treatments
    • 4.2.3 Popularity of Gene Therapy
  • 4.3 Challenges
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Reluctance to Switch to New Therapies

5. Competitive Landscape

  • 5.1 The Global Market
    • 5.1.1 Global Hemophilia A Market Share by Company
    • 5.1.2 Global Hemophilia A Factor VIII Products Market Share by Company
    • 5.1.3 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
    • 5.1.4 Global Hemophilia B Market Share by Company
    • 5.1.5 Global Hemophilia B Factor IX Products Market Share Forecast
    • 5.1.6 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast
    • 5.1.7 Key Players - Main Anti-Hemophilia Products
    • 5.1.8 Key Players - Revenue Comparison
    • 5.1.9 Key Players - Market Capital Comparison
  • 5.2 The U.S. Market
  • The U.S. Hemophilia A Market Share by Company
  • 5.3 Europe Market
  • Europe Hemophilia A Market Share by Company

6. Company Profiles

  • 6.1 Pfizer Inc.
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Bayer Group
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Sanofi S.A.
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Takeda Pharmaceutical Company
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies
  • 6.5 Novo Nordisk
    • 6.5.1 Business Overview
    • 6.5.2 Financial Overview
    • 6.5.3 Business Strategies
  • 6.6 CSL Limited
    • 6.6.1 Business Overview
    • 6.6.2 Financial Overview
    • 6.6.3 Business Strategies

List of Figures

  • Types of Hemophilia
  • Diagnosis of Hemophilia
  • Global Hemophilia Market by Value (2014-2018)
  • Global Hemophilia Market Forecast by Value (2019-2023)
  • Global Hemophilia Market by Treatment Regimen (2018)
  • Global Hemophilia Market by Type (2018)
  • Global Hemophilia A Market Forecast by Value (2018-2023)
  • Global Hemophilia A Market by Severity (2018)
  • Global Hemophilia A Market by Treatment Type (2018)
  • Global Hemophilia A Market by Treatment Regimen (2018/2023)
  • Global Hemophilia B Market Forecast by Value (2018-2023)
  • Global Hemophilia B Market by Severity (2018)
  • Global Hemophilia B Market by Treatment Type (2019)
  • Global Hemophilia B Market by Treatment Regimen (2018/2023)
  • The U.S. Hemophilia Market by Value (2014-2018)
  • The U.S. Hemophilia Market Forecast by Value (2019-2023)
  • The U.S. Hemophilia Market by Type (2018)
  • The U.S. Hemophilia A Market Forecast by Value (2018-2023)
  • The U.S. Hemophilia A Market-Treated Patient Volume Forecast (2018-2023)
  • The U.S. Hemophilia A Market-Severe Patients on Prophylactic Therapy (2018-2023)
  • The U.S. Hemophilia A Market-Severe Patients on On-Demand Therapy (2018-2023)
  • The U.S. Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy (2018-2023)
  • The U.S. Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy (2018-2023)
  • The U.S. Hemophilia B Market Forecast by Value (2018-2023)
  • The U.S. Hemophilia B Market- Treated Patients Volume Forecast (2018-2023)
  • The U.S. Hemophilia B Market- Severe Patients on Prophylaxis Therapy (2018-2023)
  • The U.S. Hemophilia B Market- Severe Patients on On-Demand Therapy (2018-2023)
  • The U.S. Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy (2018-2023)
  • The U.S. Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy (2018-2023)
  • Europe's Hemophilia Market- Patient Volume Forecast (2018-2023)
  • Europe's Hemophilia A Market- Patient Volume Forecast (2018-2023)
  • Europe's Hemophilia B Market- Patient Volume Forecast (2018-2023)
  • Global Market Share of Hemophilia A and B Patients on Prophylaxis (2018)
  • Global Identified Hemophilia Patients Volume (2011-2018)
  • Global Healthcare Expenditure (2014-2018)
  • Global Hemophilia A Market Share by Company (2017)
  • Global Hemophilia A Factor VIII Products Market Share by Company (2023/2030)
  • Global Hemophilia A FVIII Gene Therapy Market Share Forecast (2030)
  • Global Hemophilia B Market Share by Company (2017)
  • Global Hemophilia B Factor IX Products Market Share Forecast (2022/2030)
  • Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
  • The US Hemophilia A Market Share by Company (2018)
  • Europe Hemophilia B Market Share by Company (2018)
  • Pfizer Inc. Revenue Share by Major Business Segment (2018)
  • Pfizer Inc. Revenue and Net Income (2014-2018)
  • Pfizer Inc. R&D Expenses (2016-2018)
  • Bayer Group Net Sales Share by Business Segments (2018)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Bayer Group R&D Expenses (2016-2018)
  • Sanofi S.A. Revenue Share by Segments (2018)
  • Sanofi S.A. Net Sales and Net Income (2014-2018)
  • Sanofi S.A. R&D Expenses (2016-2018)
  • Takeda Pharmaceutical Company Revenue Share by Region (2019)
  • Takeda Pharmaceutical Company Revenue and Net Income (2015-2019)
  • Takeda Pharmaceutical Company R&D Expenses (2017-2019)
  • Novo Nordisk Net Sales Share by Business Segments (2018)
  • Novo Nordisk Net Sales and Net Profit (2014-2018)
  • Novo Nordisk R&D Expenses (2016-2018)
  • CSL Limited Revenue Share by Segments (2018)
  • CSL Limited Sales Revenue and Net Profit (2014-2019)
  • CSL Limited R&D Expenses (2016-2018)

List of Tables

  • Signs & Symptoms of Hemophilia
  • Extended Half Life Products (2018)
  • Development of New Novel Hemophilia Treatments (2018)
  • Hemophilia Gene Therapy Candidates (2018)
  • Key Players - Main Anti-Hemophilia Products
  • Key Players - Revenue Comparison (2018)
  • Key Players - Market Capital Comparison (2019)
  • Major Products Developed by Pfizer Inc. (2018)
  • Major Products Developed by Bayer Group (2018)
  • Novo Nordisk Product Pipeline (2018)
Back to Top